Lorraine Jones-Brando1, Faith Dickerson2, Glen Ford3, Cassie Stallings2, Andrea Origoni2, Emily Katsafanas2, Kevin Sweeney2, Amalia Squire2, Sunil Khushalani2, Robert Yolken4. 1. The Stanley Neurovirology Laboratory, Department of Pediatrics, Johns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD 21287, United States. Electronic address: lbrando@jhmi.edu. 2. The Stanley Research Program at Sheppard Pratt, Baltimore, MD, United States. 3. VanPelt Biosciences, Rockville, MD, United States. 4. The Stanley Neurovirology Laboratory, Department of Pediatrics, Johns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD 21287, United States.
Abstract
BACKGROUND: An atypical immune response to Epstein-Barr virus (EBV) infection has been associated with several complex diseases including schizophrenia. The etiology of MDD is unclear; host immune response to EBV infection could play a role. METHODS: We utilized solid phase immunoassays and western blots to measure antibodies to EBV virions, specific viral proteins, and 5 other herpesviruses in 87 individuals with MDD and 312 control individuals. RESULTS: Individuals with MDD had significantly reduced levels of reactivity to EBV Nuclear Antigen-1. Quantitative levels of antibodies to EBV virions and Viral Capsid Antigen did not differ between groups. Individuals with decreased levels of anti-Nuclear Antigen-1, or elevated levels of anti-virion had increased odds of being in the MDD group. The odds of MDD were elevated in individuals who had the combination of high levels of anti-virion and low levels of anti-Nuclear Antigen-1 (OR =13.6). Western blot analysis corroborated decreased reactivity to Nuclear Antigen-1 in the MDD group and revealed altered levels of antibodies to other EBV proteins. There was a trend towards decreased levels of antibodies to varicella virus in the group of individuals with MDD. LIMITATIONS: The MDD sample size was relatively small. There could be unmeasured factors that account for the association between MDD and the immune response to EBV. CONCLUSIONS: Individuals with MDD have altered levels and patterns of antibodies to EBV antigens. This atypical response could contribute to the immunopathology of MDD. Therapeutic interventions available for treatment of EBV infection could potentially be of benefit in MDD.
BACKGROUND: An atypical immune response to Epstein-Barr virus (EBV) infection has been associated with several complex diseases including schizophrenia. The etiology of MDD is unclear; host immune response to EBVinfection could play a role. METHODS: We utilized solid phase immunoassays and western blots to measure antibodies to EBV virions, specific viral proteins, and 5 other herpesviruses in 87 individuals with MDD and 312 control individuals. RESULTS: Individuals with MDD had significantly reduced levels of reactivity to EBV Nuclear Antigen-1. Quantitative levels of antibodies to EBV virions and Viral Capsid Antigen did not differ between groups. Individuals with decreased levels of anti-Nuclear Antigen-1, or elevated levels of anti-virion had increased odds of being in the MDD group. The odds of MDD were elevated in individuals who had the combination of high levels of anti-virion and low levels of anti-Nuclear Antigen-1 (OR =13.6). Western blot analysis corroborated decreased reactivity to Nuclear Antigen-1 in the MDD group and revealed altered levels of antibodies to other EBV proteins. There was a trend towards decreased levels of antibodies to varicella virus in the group of individuals with MDD. LIMITATIONS: The MDD sample size was relatively small. There could be unmeasured factors that account for the association between MDD and the immune response to EBV. CONCLUSIONS: Individuals with MDD have altered levels and patterns of antibodies to EBV antigens. This atypical response could contribute to the immunopathology of MDD. Therapeutic interventions available for treatment of EBVinfection could potentially be of benefit in MDD.
Authors: Sina Haeri; Nell Johnson; Arthur M Baker; Alison M Stuebe; Christena Raines; David A Barrow; Kim A Boggess Journal: Obstet Gynecol Date: 2011-04 Impact factor: 7.661
Authors: J S Tzartos; G Khan; A Vossenkamper; M Cruz-Sadaba; S Lonardi; E Sefia; A Meager; A Elia; J M Middeldorp; M Clemens; P J Farrell; G Giovannoni; U-C Meier Journal: Neurology Date: 2011-12-07 Impact factor: 9.910
Authors: Antonella Farina; Mara Cirone; Michael York; Stefania Lenna; Cristina Padilla; Sarah Mclaughlin; Alberto Faggioni; Robert Lafyatis; Maria Trojanowska; Giuseppina A Farina Journal: J Invest Dermatol Date: 2013-10-11 Impact factor: 8.551
Authors: Faith Dickerson; Emily Katsafanas; Andrea Origoni; Amalia Squire; Sunil Khushalani; Theresa Newman; Kelly Rowe; Cassie Stallings; Christina L G Savage; Kevin Sweeney; Tanya T Nguyen; Alan Breier; Donald Goff; Glen Ford; Lorraine Jones-Brando; Robert Yolken Journal: Schizophr Res Date: 2021-01-12 Impact factor: 4.939